Sequent Scientific Share Price Target 2025 To 2030
Sequent Scientific Ltd. is a well-established pharmaceutical company, primarily focused on animal health. With its innovative solutions and commitment to quality, the company has made significant strides in the global veterinary market.
In this article we explore the future share price targets of Sequent Scientific, providing a year-by-year analysis based on market trends, technical data, and fundamentals.
Table of Contents
- 1 Basic Details of Sequent Scientific Ltd.
- 2 About Sequent Scientific’s Business
- 3 Sequent scientific share price chart: LIVE
- 4 Sequent Scientific Share Price Target 2024
- 5 Sequent Scientific Share Price Target 2025
- 6 Sequent Scientific Share Price Target 2026
- 7 Sequent Scientific Price Target 2027
- 8 SEQUENT Share Price Target 2028
- 9 Sequent Scientific Share Price Target 2029
- 10 Sequent Scientific Share Price Target 2030
- 11 Technical Analysis
- 12 Fundamental
- 13 Sequent Scientific Quarterly Result
- 14 Why Sequent Scientific Share Price Falling and Increase
- 15 Conclusion
Basic Details of Sequent Scientific Ltd.
| Company Name | Sequent Scientific Ltd. |
| Business Sector | Pharmaceuticals (Animal Health) |
| Stock Symbol | SEQUENT |
| NSE Listing Status | Listed |
| BSE Listing Status | Listed |
| Official Website | https://sequent.in/ |
About Sequent Scientific’s Business
Sequent Scientific Ltd. is a global leader in animal health pharmaceuticals, offering a range of products that include active pharmaceutical ingredients (APIs) and formulations.
The company operates through state-of-the-art manufacturing units and is known for its robust R&D capabilities. With a presence in multiple countries, Sequent caters to a broad client base, enhancing its global influence in veterinary medicine.
In 2024, Sequent Scientific’s stock has shown a positive trajectory, benefiting from increased market activity and investor interest. Technical indicators signal a strong trend with the stock expected to maintain an upward path.
| Year | Low Approx | High Approx |
|---|---|---|
| 2024 | ₹160 | ₹220 |
Sequent Scientific is projected to continue its growth in 2025, backed by consistent revenue gains and expanded global operations. Investors may look forward to steady appreciation as the company enhances its market share.
| Year | Low Approx | High Approx |
|---|---|---|
| 2025 | ₹208 | ₹366 |
The outlook for 2026 is optimistic, with Sequent likely capitalizing on its advanced product portfolio and strategic partnerships. Market conditions and sectoral growth are expected to boost its stock value.
| Year | Low Approx | High Approx |
|---|---|---|
| 2026 | ₹366 | ₹704 |
Sequent Scientific Price Target 2027
By 2027, Sequent Scientific could see further gains as it strengthens its global footprint and focuses on technological innovation in animal health products. This period may mark the realization of long-term growth strategies.
| Year | Low Approx | High Approx |
|---|---|---|
| 2027 | ₹700 | ₹1351 |
Sequent’s growth trajectory is likely to remain steady in 2028, driven by sustained demand in the veterinary sector and continued investments in research and development.
| Year | Low Approx | High Approx |
|---|---|---|
| 2028 | ₹1350 | ₹1621 |
The year 2029 could bring new opportunities as Sequent potentially diversifies its product range and enters new markets. This expansion may contribute to further stock price appreciation.
| Year | Low Approx | High Approx |
|---|---|---|
| 2029 | ₹1600 | ₹1945 |
Looking ahead to 2030, Sequent Scientific is anticipated to reach new heights, supported by strong fundamentals, continuous innovation, and a growing global market share. The company’s investments in advanced veterinary solutions may play a crucial role in shaping its long-term success.
| Year | Low Approx | High Approx |
|---|---|---|
| 2030 | ₹1900 | ₹2334 |
Technical Analysis
The stock’s 50-day and 200-day exponential moving averages (EMAs) indicate an overall bullish trend. The price has consistently stayed above key support levels, confirming investor confidence.
Fundamental
- 🏢 Market Cap: ₹ 4,779 Cr.
- 💰 Current Price: ₹ 191
- 📈📉 52-Week High / Low: ₹ 241 / ₹ 91.8
- 📊 Stock P/E: 401
- 📚 Book Value: ₹ 43.6
- 💸 Dividend Yield: 0.00%
- 🔄 ROCE (Return on Capital Employed): 0.53%
- 💹 ROE (Return on Equity): 0.22%
- 🪙 Face Value: ₹ 2.00
- 📈 52-Week High: ₹ 240.70
- 📉 52-Week Low: ₹ 92.05
| Shareholder Type | Holding Percentage |
|---|---|
| Promoter | 52.76% |
| Public | 30.63% |
| Mutual Funds | 7.41% |
| FII (Foreign Institutional Investors) | 6.45% |
| Other Institutions | 2.58% |
Sequent Scientific Quarterly Result
Sequent Scientific’s quarterly results have shown consistent growth, driven by strategic investments and market expansion. The company continues to post healthy profits and increased earnings per share (EPS), indicating solid financial health.
| Quarter | Revenue (₹ Cr) | Net Profit (₹ Cr) | EPS (₹) |
|---|---|---|---|
| Q1 2024 | 36.77 | 3.76 | 0.15 |
| Q2 2024 | 57.67 | 4.50 | 0.18 |
This analysis provides investors with an overview of Sequent Scientific Ltd.’s potential share price movements up to 2030, supported by technical trends and fundamental performance.
Understanding why a stock’s price falls or rises is essential for investors. Sequent Scientific Ltd., like many other stocks, experiences fluctuations due to various technical and fundamental factors. Here, we’ll break down the main reasons for both the stock’s declines and gains.
| Reason | Price Falling | Price Rising |
|---|---|---|
| Quarterly Results | Weak earnings or revenue | Strong earnings or revenue |
| Market Sentiment | Bearish market trends | Bullish market trends |
| Regulatory Challenges | Negative regulatory news | Positive regulatory developments |
| Technical Indicators | Hitting resistance levels | Breaking above resistance levels |
| Product Announcements | Lack of new products | New product launches or approvals |
| Partnerships/Expansions | Absence of strategic moves | New partnerships and market expansions |
Conclusion
Sequent Scientific Ltd. is a notable player in the pharmaceutical industry, with a significant market capitalization and a history of fluctuating stock prices. While its high P/E ratio and relatively low ROCE and ROE indicate some fundamental challenges, the company’s shareholding pattern and market performance reflect investor interest.
